Mainz Biomed (MYNZ) announces positive topline results from its feasibility study, examining a non-invasive blood-based screening test for the early detection of pancreatic cancer, initiated earlier this year. The study confirmed the strong clinical accuracy and utility of licensed proprietary biomarkers from Liquid Biosciences for developing an innovative screening test for pancreatic cancer. Researchers evaluated 18 licensed biomarkers across multiple candidate panels to streamline assay complexity. The leading panel achieved 100% sensitivity and 95% specificity, successfully distinguishing pancreatic cancer patients from healthy controls in a 30-subject cohort, reflecting different stages of the disease as well as precursors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ:
- Mainz Biomed Enters $10 Million Equity Distribution Agreement with Maxim Group
- Mainz Biomed to present at WEO CRC Screening Committee Meeting
- Mainz Biomed Reports Financial Results for First Half of 2025
- Mainz Biomed announces commercial launch of ColoAlert in Switzerland
- Mainz Biomed announces registration of ColoAlert in the U.K.